LFST
NEUTRAL
$6.4
Live
LifeStance Health Group, Inc. · NASDAQ
Target $9.83
(+53.6%)
$3.74
52W Range
$8.09
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 13, 2026
Market cap
$2.45B
P/E
320.0
ROE
0.7%
Profit margin
0.7%
Debt/Equity
0.31
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
80%
LFST presents a stable but precarious financial profile with a Piotroski F-Score of 4/9 and no Altman Z-Score provided for bankruptcy risk assessment. While the company has successfully transitioned toward profitability with a promising forward P/E of 16.74, it trades at a massive premium compared to its Graham Number ($1.33) and Intrinsic Value ($0.14). Strong revenue growth of 17.4% is offset by razor-thin profit margins (0.68%) and aggressive insider selling totaling $32.51M. The stock is currently a speculative play on earnings expansion rather than a value-driven investment.
Key Strengths
Low Debt/Equity ratio of 0.31 indicating manageable leverage
Consistent revenue growth of 17.4% YoY and Q/Q
Successful transition from historical losses to positive EPS
Healthy liquidity with a Current Ratio of 1.65
Attractive Forward P/E (16.74) relative to trailing P/E
Key Risks
Extreme trailing P/E ratio of 320.00
Heavy insider selling totaling $32.51M in the last 6 months
Razor-thin net profit margins of 0.68%
Significant disconnect between current price ($6.40) and Graham Number ($1.33)
Bearish technical trend (0/100 score)
AI Fair Value Estimate
Based on comprehensive analysis
$4.5
-29.7% below current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
35
Weak
20
70
30
55
0
AI Verdict
Speculative Growth
Key drivers: Earnings transition, Revenue growth, Insider divestment, Valuation gap
Confidence
85%
Value
20/100
Stock trades at a significant premium to defensive fair value, relying entirely on future growth projections.
Positives
- Reasonable Forward P/E
Watchpoints
- Trailing P/E of 320
- Price far exceeds Graham Number ($1.33)
- Intrinsic value is negligible ($0.14)
Future
70/100
Growth metrics are strong, and the shift to profitability is the primary bullish catalyst.
Positives
- 17.4% Revenue growth
- Positive EPS surprise trend
- Analyst target price of $9.83
Watchpoints
- Thin margins limit error room
Past
30/100
Long-term performance has been poor, though the most recent quarters show a turnaround.
Positives
- Recent 6-month price recovery (+26.7%)
Watchpoints
- 5-year return of -70.8%
- History of earnings misses in 2021-2023
Health
55/100
Balance sheet is clean, but operational efficiency (margins) remains weak.
Positives
- Low Debt/Equity (0.31)
- Current Ratio > 1.5
Watchpoints
- Piotroski F-Score of 4/9 (Stable but not strong)
Dividend
0/100
Company is in a growth/recovery phase and does not return capital to shareholders.
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0% payout ratio
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$6.4
Analyst Target
$9.83
Upside/Downside
+53.6%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for LFST and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
LFST
LifeStance Health Group, Inc.
Primary
|
-70.8% | -18.8% | -5.5% | +26.7% | -3.6% | +1.4% |
|
APLS
Apellis Pharmaceuticals, Inc.
Peer
|
-59.8% | -70.9% | -22.3% | -23.8% | -15.1% | -5.6% |
|
ATEC
Alphatec Holdings, Inc.
Peer
|
+4.7% | +20.4% | +33.9% | +44.4% | -24.8% | -11.9% |
|
HTFL
Heartflow, Inc.
Peer
|
-10.1% | -10.1% | -10.1% | -19.5% | +21.3% | +8.5% |
|
LMAT
LeMaitre Vascular, Inc.
Peer
|
+140.7% | +121.7% | +42.2% | +33.8% | +6.0% | +5.7% |
LFS
LifeStance Health Group, Inc.
Primary
5Y
-70.8%
3Y
-18.8%
1Y
-5.5%
6M
+26.7%
1M
-3.6%
1W
+1.4%
APL
Apellis Pharmaceuticals, Inc.
Peer
5Y
-59.8%
3Y
-70.9%
1Y
-22.3%
6M
-23.8%
1M
-15.1%
1W
-5.6%
ATE
Alphatec Holdings, Inc.
Peer
5Y
+4.7%
3Y
+20.4%
1Y
+33.9%
6M
+44.4%
1M
-24.8%
1W
-11.9%
HTF
Heartflow, Inc.
Peer
5Y
-10.1%
3Y
-10.1%
1Y
-10.1%
6M
-19.5%
1M
+21.3%
1W
+8.5%
LMA
LeMaitre Vascular, Inc.
Peer
5Y
+140.7%
3Y
+121.7%
1Y
+42.2%
6M
+33.8%
1M
+6.0%
1W
+5.7%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
320.0
Forward P/E
16.74
PEG Ratio
N/A
P/B Ratio
1.63
P/S Ratio
1.72
EV/Revenue
1.91
EV/EBITDA
34.04
Market Cap
$2.45B
Profitability
Profit margins and return metrics
Profit Margin
0.68%
Operating Margin
4.74%
Gross Margin
32.37%
ROE
0.65%
ROA
0.73%
Growth
Revenue and earnings growth rates
Revenue Growth
+17.4%
Earnings Growth
N/A
Q/Q Revenue Growth
+17.43%
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
0.31
Low debt
Current Ratio
1.65
Good
Quick Ratio
1.38
Good
Cash/Share
$0.64
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.4B
Gross Margin
33.0%
Op. Margin
4.7%
Net Margin
3.1%
Total Assets
$2.2B
Liabilities
$0.7B
Equity
$1.5B
Debt/Equity
0.45x
Operating CF
$0.1B
CapEx
$-0.0B
Free Cash Flow
$0.0B
FCF Yield
81%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-05-07
$N/A
2026-02-25
$0.09
+64.3% surprise
2025-11-06
$0.01
-63.7% surprise
2025-08-07
$-0.01
+61.6% surprise
Healthcare Sector Comparison
Comparing LFST against 291 companies in the Healthcare sector
(20 bullish, 99 neutral, 172 bearish)
P/E Ratio
320.0
This Stock
vs
87.11
Sector Avg
+267.3%
(Expensive)
Return on Equity (ROE)
0.65%
This Stock
vs
-49.88%
Sector Avg
-101.3%
(Below Avg)
Profit Margin
0.68%
This Stock
vs
-9.43%
Sector Avg
-107.2%
(Weaker)
Debt to Equity
0.31
This Stock
vs
3.74
Sector Avg
-91.7%
(Less Debt)
Revenue Growth
17.4%
This Stock
vs
80.78%
Sector Avg
-78.5%
(Slower)
Current Ratio
1.65
This Stock
vs
3.72
Sector Avg
-55.6%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
LFST
LifeStance Health Group, Inc.
|
NEUTRAL | $2.45B | 320.0 | 0.7% | 0.7% | $6.4 | |
|
APLS
Apellis Pharmaceuticals, Inc.
|
BEARISH | $2.42B | 105.22 | 7.5% | 2.2% | $18.94 | Compare |
|
ATEC
Alphatec Holdings, Inc.
|
BEARISH | $2.32B | - | -540.4% | -21.3% | $15.62 | Compare |
|
HTFL
Heartflow, Inc.
|
BEARISH | $2.31B | - | -111.4% | -66.3% | $26.95 | Compare |
|
LMAT
LeMaitre Vascular, Inc.
|
NEUTRAL | $2.61B | 45.48 | 15.8% | 23.1% | $114.62 | Compare |
LFST
LifeStance...
NEUTRAL
Mkt Cap
$2.4B
P/E
320.0
ROE
0.7%
Price
$6.4
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-09 | PAUNOVICH VUKASIN | Chief Technology Officer | Stock Award | 62,935 | - |
| 2026-03-09 | VARANAKIS ANN | Officer | Stock Award | 86,625 | - |
| 2026-03-09 | MILLER LISA K | Chief Operating Officer | Stock Award | 26,836 | - |
| 2026-03-09 | MCGROARTY RYAN | Chief Financial Officer | Stock Award | 193,046 | - |
| 2026-03-09 | BURDICK KENNETH A | Director | Stock Award | 740,504 | - |
| 2026-03-09 | BOURDON DAVID | Chief Executive Officer | Stock Award | 328,544 | - |
| 2026-03-09 | PARDO RYAN | Officer and Director | Stock Award | 145,965 | - |
| 2026-03-05 | PAUNOVICH VUKASIN | Chief Technology Officer | Stock Award | 86,331 | - |
| 2026-03-05 | VARANAKIS ANN | Officer | Stock Award | 86,331 | - |
| 2026-03-05 | MILLER LISA K | Officer | Stock Award | 107,914 | - |
| 2026-03-05 | MCGROARTY RYAN | Chief Financial Officer | Stock Award | 179,856 | - |
| 2026-03-05 | BOURDON DAVID | Chief Executive Officer | Stock Award | 395,683 | - |
| 2026-03-05 | PARDO RYAN | Officer | Stock Award | 129,496 | - |
| 2026-03-02 | BLACK DARREN M | Director | Sale | 4,314,939 | $30,247,722 |
| 2025-12-22 | BESSLER ROBERT | Director | Sale | 121,643 | $856,367 |
PAUNOVICH VUKASIN
Chief Technology Officer
2026-03-09
62,935 shares
VARANAKIS ANN
Officer
2026-03-09
86,625 shares
MILLER LISA K
Chief Operating Officer
2026-03-09
26,836 shares
MCGROARTY RYAN
Chief Financial Officer
2026-03-09
193,046 shares
BURDICK KENNETH A
Director
2026-03-09
740,504 shares
BOURDON DAVID
Chief Executive Officer
2026-03-09
328,544 shares
PARDO RYAN
Officer and Director
2026-03-09
145,965 shares
PAUNOVICH VUKASIN
Chief Technology Officer
2026-03-05
86,331 shares
VARANAKIS ANN
Officer
2026-03-05
86,331 shares
MILLER LISA K
Officer
2026-03-05
107,914 shares
MCGROARTY RYAN
Chief Financial Officer
2026-03-05
179,856 shares
BOURDON DAVID
Chief Executive Officer
2026-03-05
395,683 shares
PARDO RYAN
Officer
2026-03-05
129,496 shares
BLACK DARREN M
Director
2026-03-02
4,314,939 shares
·
$30,247,722
BESSLER ROBERT
Director
2025-12-22
121,643 shares
·
$856,367
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
9 analysts
Barclays
2026-03-06
Overweight
Overweight
Canaccord Genuity
2026-02-26
Buy
Buy
UBS
2026-02-26
Buy
Buy
Keybanc
2026-02-26
Overweight
Overweight
BTIG
2026-02-02
Buy
Buy
BTIG
2025-12-12
Buy
Buy
Barclays
2025-12-09
Overweight
BMO Capital
2025-11-13
Outperform
UBS
2025-11-07
Buy
Buy
BTIG
2025-11-06
Buy
Buy
Past News Coverage
Recent headlines mentioning LFST from our newsroom.
Newest → oldest
No matching news yet.